We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 71

Vision Eye Institute Ltd v Kitchen (no 2) 2015 QSC 66
  • King & Wood Mallesons
  • Australia
  • July 2 2015

In this case, the Queensland Supreme Court awarded a significant amount of damages for contingent loss of income flowing from a breach of contract


De-identification and medical records in NSW
  • King & Wood Mallesons
  • Australia
  • October 24 2014

Are health service providers in New South Wales obliged by the Health Records and Information Privacy Act 2002 (NSW) to de-identify medical records


Special leave to appeal refused in the VIOXX class action
  • King & Wood Mallesons
  • Australia
  • July 5 2012

The High Court of Australia has refused special leave to appeal from the full court of the Federal Court of Australia in the VIOXX class action


Australian case notes - Odisho v Bonazzi 2014 VSCA 11
  • King & Wood Mallesons
  • Australia
  • May 20 2014

In this case the appellant, a patient who suffered a thromboembolic event following the use of tranexamic acid, claimed that her doctor had


Pharmaceuticals - copyright in PIs and indirect patent infringement
  • King & Wood Mallesons
  • Australia
  • August 4 2011

In the recent decision in Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3), Justice Jagot of the Federal Court found liability for indirect patent infringement in the context of supply of a pharmaceutical product


Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year


European Court of Justice says no to patents requiring the destruction of a human embryo - an Australian perspective
  • King & Wood Mallesons
  • Australia, European Union
  • October 20 2011

Article 6(2)(c) of the European Biotech Directive excludes inventions which use human embryos for industrial or commercial purposes from patentability


Breaking news: hard Medicine for group members to take - Full Court overturns decision in VIOXX class action
  • King & Wood Mallesons
  • Australia, USA
  • October 12 2011

The Full Court of the Federal Court of Australia has overturned the 2010 decision that marked the first successful class action ruling in the world in relation to arthritis drug VIOXX


Federal Court prescribes hard medicine for Vioxx class action
  • King & Wood Mallesons
  • Australia
  • March 15 2012

The full court of the Federal Court of Australia recently overturned a damages award in the VIOXX class action, confirming once again that issues of causation are no less difficult to prove in large-scale class actions than in individual proceedings


Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think
  • King & Wood Mallesons
  • Australia
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18